Denali Therapeutics
DNLI
204 hedge funds and large institutions have $6.13B invested in Denali Therapeutics in 2020 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 62 increasing their positions, 67 reducing their positions, and 24 closing their positions.
408% more call options, than puts
Call options by funds: $29.3M | Put options by funds: $5.76M
146% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 24
107% more capital invested
Capital invested by funds: $2.96B → $6.13B (+$3.17B)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
20% more funds holding
Funds holding: 170 → 204 (+34)
7% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 67
4.18% less ownership
Funds ownership: 78.09% → 73.91% (-4.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Crestline Management
Fort Worth,
Texas
|
+$439M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$127M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$82.4M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$79.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$196M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$82.1M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$53.1M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$51.6M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$40.9M |
DNLI Hedge Fund Activity: Q4 2020 in Review
204 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q4 2020, worth a combined $6.13B — up 107% from $2.96B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new DNLI positions and 24 closed out — a net gain of 35 holders — while 62 added to existing stakes and 67 trimmed.
The largest buyer was Crestline Management, adding an estimated $439M. The largest seller was Flagship Pioneering, cutting an estimated $196M.
- 204 institutional investors held Denali Therapeutics (DNLI) as of Q4 2020, up from 170 in Q3 2020.
- Funds reported $6.13B of Denali Therapeutics stock for Q4 2020, up 107% quarter-over-quarter.
- 59 funds opened new Denali Therapeutics positions in Q4 2020 and 24 closed out, a net change of +35 holders.
- The largest Denali Therapeutics buyer in Q4 2020 was Crestline Management, an estimated $439M added.
- The largest Denali Therapeutics seller in Q4 2020 was Flagship Pioneering, an estimated $196M sold.
Based on aggregated 13F filings for Q4 2020.